The U.S. Supreme Court declined to hear Eli Lilly’s constitutional challenge to the False Claims Act’s qui tam mechanism, preserving one of the government’s most potent civil fraud enforcement tools. The petition arose from litigation brought by whistleblower Ronald Streck, who accused Lilly of misconduct tied to Medicaid drug rebate reporting.

By denying review, the Court leaves in place lower-court rulings that allowed the case to proceed and, more broadly, avoids reopening a recurring defense-side attack on the False Claims Act’s structure.